FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4307114517> ?p ?o ?g. }

• W4307114517 endingPage "31" @default.
• W4307114517 startingPage "22" @default.
• W4307114517 abstract "Abstract Background Several SARS-CoV-2 vaccines have been shown to provide protection against COVID-19 hospitalization and death. However, some evidence suggests that notable waning in effectiveness against these outcomes occurs within months of vaccination. We undertook a pooled analysis across the four nations of the UK to investigate waning in vaccine effectiveness (VE) and relative vaccine effectiveness (rVE) against severe COVID-19 outcomes. Methods We carried out a target trial design for first/second doses of ChAdOx1(Oxford–AstraZeneca) and BNT162b2 (Pfizer–BioNTech) with a composite outcome of COVID-19 hospitalization or death over the period 8 December 2020 to 30 June 2021. Exposure groups were matched by age, local authority area and propensity for vaccination. We pooled event counts across the four UK nations. Results For Doses 1 and 2 of ChAdOx1 and Dose 1 of BNT162b2, VE/rVE reached zero by approximately Days 60–80 and then went negative. By Day 70, VE/rVE was –25% (95% CI: –80 to 14) and 10% (95% CI: –32 to 39) for Doses 1 and 2 of ChAdOx1, respectively, and 42% (95% CI: 9 to 64) and 53% (95% CI: 26 to 70) for Doses 1 and 2 of BNT162b2, respectively. rVE for Dose 2 of BNT162b2 remained above zero throughout and reached 46% (95% CI: 13 to 67) after 98 days of follow-up. Conclusions We found strong evidence of waning in VE/rVE for Doses 1 and 2 of ChAdOx1, as well as Dose 1 of BNT162b2. This evidence may be used to inform policies on timings of additional doses of vaccine." @default.
• W4307114517 created "2022-10-27" @default.
• W4307114517 creator A5014846731 @default.
• W4307114517 creator A5017489363 @default.
• W4307114517 creator A5018930457 @default.
• W4307114517 creator A5021335144 @default.
• W4307114517 creator A5029484271 @default.
• W4307114517 creator A5033011934 @default.
• W4307114517 creator A5038083978 @default.
• W4307114517 creator A5038431304 @default.
• W4307114517 creator A5045308568 @default.
• W4307114517 creator A5052532012 @default.
• W4307114517 creator A5057590353 @default.
• W4307114517 creator A5065866497 @default.
• W4307114517 creator A5066306728 @default.
• W4307114517 creator A5072817577 @default.
• W4307114517 creator A5080557082 @default.
• W4307114517 creator A5086157485 @default.
• W4307114517 date "2022-10-22" @default.
• W4307114517 modified "2023-10-16" @default.
• W4307114517 title "Waning of first- and second-dose ChAdOx1 and BNT162b2 COVID-19 vaccinations: a pooled target trial study of 12.9 million individuals in England, Northern Ireland, Scotland and Wales" @default.
• W4307114517 cites W2298338128 @default.
• W4307114517 cites W3044418073 @default.
• W4307114517 cites W3094542430 @default.
• W4307114517 cites W3111255098 @default.
• W4307114517 cites W3111590711 @default.
• W4307114517 cites W3131688063 @default.
• W4307114517 cites W3158123254 @default.
• W4307114517 cites W3196374018 @default.
• W4307114517 cites W3201177512 @default.
• W4307114517 cites W3212840395 @default.
• W4307114517 cites W4200431335 @default.
• W4307114517 cites W4205483821 @default.
• W4307114517 cites W4225130422 @default.
• W4307114517 cites W4226054307 @default.
• W4307114517 cites W4226246286 @default.
• W4307114517 cites W4226310502 @default.
• W4307114517 cites W4226376477 @default.
• W4307114517 doi "https://doi.org/10.1093/ije/dyac199" @default.
• W4307114517 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36272418" @default.
• W4307114517 hasPublicationYear "2022" @default.
• W4307114517 type Work @default.
• W4307114517 citedByCount "5" @default.
• W4307114517 countsByYear W43071145172022 @default.
• W4307114517 countsByYear W43071145172023 @default.
• W4307114517 crossrefType "journal-article" @default.
• W4307114517 hasAuthorship W4307114517A5014846731 @default.
• W4307114517 hasAuthorship W4307114517A5017489363 @default.
• W4307114517 hasAuthorship W4307114517A5018930457 @default.
• W4307114517 hasAuthorship W4307114517A5021335144 @default.
• W4307114517 hasAuthorship W4307114517A5029484271 @default.
• W4307114517 hasAuthorship W4307114517A5033011934 @default.
• W4307114517 hasAuthorship W4307114517A5038083978 @default.
• W4307114517 hasAuthorship W4307114517A5038431304 @default.
• W4307114517 hasAuthorship W4307114517A5045308568 @default.
• W4307114517 hasAuthorship W4307114517A5052532012 @default.
• W4307114517 hasAuthorship W4307114517A5057590353 @default.
• W4307114517 hasAuthorship W4307114517A5065866497 @default.
• W4307114517 hasAuthorship W4307114517A5066306728 @default.
• W4307114517 hasAuthorship W4307114517A5072817577 @default.
• W4307114517 hasAuthorship W4307114517A5080557082 @default.
• W4307114517 hasAuthorship W4307114517A5086157485 @default.
• W4307114517 hasBestOaLocation W43071145171 @default.
• W4307114517 hasConcept C116675565 @default.
• W4307114517 hasConcept C126322002 @default.
• W4307114517 hasConcept C144024400 @default.
• W4307114517 hasConcept C149923435 @default.
• W4307114517 hasConcept C159047783 @default.
• W4307114517 hasConcept C22070199 @default.
• W4307114517 hasConcept C2779134260 @default.
• W4307114517 hasConcept C3006700255 @default.
• W4307114517 hasConcept C3007834351 @default.
• W4307114517 hasConcept C3008058167 @default.
• W4307114517 hasConcept C524204448 @default.
• W4307114517 hasConcept C71924100 @default.
• W4307114517 hasConceptScore W4307114517C116675565 @default.
• W4307114517 hasConceptScore W4307114517C126322002 @default.
• W4307114517 hasConceptScore W4307114517C144024400 @default.
• W4307114517 hasConceptScore W4307114517C149923435 @default.
• W4307114517 hasConceptScore W4307114517C159047783 @default.
• W4307114517 hasConceptScore W4307114517C22070199 @default.
• W4307114517 hasConceptScore W4307114517C2779134260 @default.
• W4307114517 hasConceptScore W4307114517C3006700255 @default.
• W4307114517 hasConceptScore W4307114517C3007834351 @default.
• W4307114517 hasConceptScore W4307114517C3008058167 @default.
• W4307114517 hasConceptScore W4307114517C524204448 @default.
• W4307114517 hasConceptScore W4307114517C71924100 @default.
• W4307114517 hasFunder F4320311904 @default.
• W4307114517 hasFunder F4320313245 @default.
• W4307114517 hasFunder F4320314731 @default.
• W4307114517 hasFunder F4320318247 @default.
• W4307114517 hasFunder F4320319992 @default.
• W4307114517 hasFunder F4320319994 @default.
• W4307114517 hasFunder F4320320853 @default.
• W4307114517 hasFunder F4320334626 @default.
• W4307114517 hasFunder F4320334627 @default.
• W4307114517 hasFunder F4320334630 @default.
• W4307114517 hasIssue "1" @default.

• next